NOMAD Bioscience Receives the Official “DECISION TO GRANT A EUROPEAN PATENT” From European Patent Office for Its Patent Application ‘Colicin M for the control of EHEC’

NOMAD Bioscience GmbH has announced that the European Patent Office has issued the „DECISION TO GRANT A EUROPEAN PATENT“ for the NOMAD’s patent application ‘Colicin M for the control of EHEC’, European Patent No. 3 097 783. This is the second issued patent which protects NOMAD’s Colicins, non-antibiotic antibacterial proteins and the company’s lead product candidates for food and feed safety market. The first patent of this family was granted in the United States in February, 2019; US Patent No. 10,201,168.

Enterohemorrhagic or Shiga toxin-producing Escherichia coli (EHEC) contaminating food products are a major cause of bacterial enteric infections in USA and worldwide. NOMAD product candidates described and claimed in the patent application are simple mixtures of two or more bacterial Colicins produced in plants and applied at very low concentrations; the products are highly and broadly active against all major pathogenic E. coli strains causing food poisoning defined by USDA/FSIS as requiring priority control (‚Big Seven‘).

‘We are very pleased that the European Patent Office has allowed all essential claims in our submitted application’, said Prof. Dr. Yuri Gleba, NOMAD’s CEO. ‘Our Colicin product candidates have already received GRAS regulatory clearance in USA from FDA or FDA/USDA as food additives and food processing aids (GRN 593, GRN 676 and GRN 775). These regulatory approvals, together with the broad patent protection, significantly strengthen NOMAD’s position as the leading provider of novel safety solutions for food and feed market.’

In addition to Colicins, other plant-produced Bacteriocins of bacterial and bacteriophage origins are being developed by NOMAD as inexpensive food additives and food processing aids for the broad control of most common bacterial pathogens (Escherichia coli, Salmonella enterica and Clostridium perfringens) in food products. NOMAD is also actively developing Bacteriocins as medical alternatives to antibiotics, with its pre-clinical research focused on novel antibacterial proteins for control of major multi-drug resistant Gram-negative pathogens including Escherichia, Pseudomonas and Klebsiella. NOMAD is aggressively filing for patent protection of all its inventions related to Bacteriocins as food additives and medicines.

About NOMAD Bioscience GmbH.
Nomad Bioscience GmbH is a plant biotechnology company developing a broad range of biotechnology products manufactured in plants. Corporate offices are headquartered in Munich, Germany and the Company’s Research Division is located in Halle, Germany. NOMAD Bioscience GmbH has two subsidiary companies: Nambawan Biotech GmbH (Halle, Germany) and UAB Nomads (Vilnius, Lithuania).
Contact info: gleba@nomadbioscience.com